BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 38269619)

  • 41. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.
    Apollonio B; Ioannou N; Papazoglou D; Ramsay AG
    Front Oncol; 2021; 11():626818. PubMed ID: 33842331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Qin Huang formula enhances the effect of Adriamycin in B-cell lymphoma via increasing tumor infiltrating lymphocytes by targeting toll-like receptor signaling pathway.
    Li W; Lv L; Ruan M; Xu J; Zhu W; Li Q; Jiang X; Zheng L; Zhu W
    BMC Complement Med Ther; 2022 Jul; 22(1):185. PubMed ID: 35818037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma.
    Bröckelmann PJ; de Jong MRW; Jachimowicz RD
    Cells; 2020 Oct; 9(10):. PubMed ID: 33066395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antifibrotic therapy to normalize the tumor microenvironment.
    Hauge A; Rofstad EK
    J Transl Med; 2020 May; 18(1):207. PubMed ID: 32434573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives.
    Nagl L; Horvath L; Pircher A; Wolf D
    Front Cell Dev Biol; 2020; 8():766. PubMed ID: 32974337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.
    Cao X; Wang Y; Zhang W; Zhong X; Gunes EG; Dang J; Wang J; Epstein AL; Querfeld C; Sun Z; Rosen ST; Feng M
    Blood; 2022 Jun; 139(22):3290-3302. PubMed ID: 35134139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic challenges in peripheral T-cell lymphoma.
    Luan Y; Li X; Luan Y; Luo J; Dong Q; Ye S; Li Y; Li Y; Jia L; Yang J; Yang DH
    Mol Cancer; 2024 Jan; 23(1):2. PubMed ID: 38178117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.
    Gsottberger F; Brandl C; Wendland K; Petkovic S; Emmerich C; Erber R; Geppert C; Hartmann A; Mackensen A; Nitschke L; Müller F
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of tumor-associated macrophages in hematological malignancies.
    Komohara Y; Niino D; Ohnishi K; Ohshima K; Takeya M
    Pathol Int; 2015 Apr; 65(4):170-6. PubMed ID: 25707506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The tumor microenvironment: shaping cancer progression and treatment response.
    Desai SA; Patel VP; Bhosle KP; Nagare SD; Thombare KC
    J Chemother; 2024 Jan; ():1-30. PubMed ID: 38179655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic Targeting of the Tumor Microenvironment.
    Bejarano L; Jordāo MJC; Joyce JA
    Cancer Discov; 2021 Apr; 11(4):933-959. PubMed ID: 33811125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Wnt Signaling in the Tumor Microenvironment.
    Ruan Y; Ogana H; Gang E; Kim HN; Kim YM
    Adv Exp Med Biol; 2021; 1270():107-121. PubMed ID: 33123996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.
    Jacobs B; Gebel V; Heger L; Grèze V; Schild H; Dudziak D; Ullrich E
    Front Immunol; 2021; 12():670540. PubMed ID: 34054844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
    Buoncervello M; Gabriele L; Toschi E
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TME-Related Biomimetic Strategies Against Cancer.
    Peng C; Xu Y; Wu J; Wu D; Zhou L; Xia X
    Int J Nanomedicine; 2024; 19():109-135. PubMed ID: 38192633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural Biology of the Tumor Microenvironment.
    Freeman JW
    Adv Exp Med Biol; 2021; 1350():91-100. PubMed ID: 34888845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.